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ABSTRACT
Introduction: Comparisons of the glycemic
durability between thiazolidinediones (TZDs)
and dipeptidyl peptidase-4 (DPP-4) inhibitors
remain insufficient. This study aimed to find
clues for the differences in glycemic durability
between TZDs and DPP-4 inhibitors by com-
paring the insulin resistance and b-cell function
among patients using these agents.
Methods: A total of 241 patients with type 2
diabetes mellitus (T2DM) treated with either
pioglitazone (a TZD) or DPP-4 inhibitors as
combination therapy with metformin for at
least 1 year were analyzed. A propensity score
based on the patients’ baseline characteristics
and glycated hemoglobin (HbA1c) was used to
match them. Indices for insulin resistance and
secretory function of b-cells, namely the
homeostasis model assessment of insulin resis-
tance (HOMA-IR) or b-cells (HOMA-b), were
calculated and compared. Multiple regression
analysis was performed to find the independent
variables correlated with b-cell function or
insulin resistance.
Results: Evaluation of the data from 168 mat-
ched patients with T2DM showed that TZD
users had significantly better insulin sensitivity
compared with DPP-4 inhibitor users (HOMA-IR
2.3 ± 1.9 vs. 3.5 ± 3.2, p = 0.003). Conversely,
DPP-4 inhibitor users secreted more insulin
than TZD users (HOMA-b 45.7 ± 31.6 vs.
61.4 ± 49.5, p = 0.016). Multiple linear regres-
sion analysis showed that these agents were
independently associated with both insulin
resistance and b-cell function.
Conclusion: TZD users showed significantly
better insulin sensitivity, whereas DPP-4 inhi-
bitor users secreted more insulin from b-cells
under similar glycemic control.
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
metabolic disease characterized by progressive
deterioration of insulin sensitivity and b-cell
function [1]. Currently, there is no way to block
the worsening of b-cell function completely;
however, antidiabetic agents (ADAs) can par-
tially slow down the progression of b-cell fail-
ure, with varying effects according to their
mechanisms of action [2].
The A Diabetes Outcome Progression Trial
(ADOPT) compared the monotherapy failure
rates of three ADAs, namely metformin, gly-
buride, and rosiglitazone, and concluded that
rosiglitazone had the most durable glycemic
control effects [3]. A German study published in
the same year as ADOPT revealed that pioglita-
zone added to metformin monotherapy affor-
ded better long-term (3.5-year) glycemic control
compared with the glibenclamide-added group
[4]. These studies highlight the importance of
improving insulin resistance because thiazo-
lidinediones (TZDs), which primarily focus on
insulin sensitivity, have a comparatively supe-
rior effect in slowing down the process of b-cell
failure, as compared with other classes of ADAs.
This is particularly important for patients with
T2DM in East Asia such as Korea, whose b-cell
function is often reduced at the time of diag-
nosis [5].
TZDs improve insulin resistance by activat-
ing peroxisome proliferator-activated receptor c
(PPARc) [6], especially in adipose and liver tissue
[7]. They are the only class of ADAs which pri-
marily target insulin sensitivity, the core
mechanism of T2DM. However, because of
some safety issues such as fulminant hepatitis
[8] and myocardial infarction [9], pioglitazone
has become virtually the only TZD used around
the world and has a relatively small portion of
the current ADA market.
Dipeptidyl peptidase-4 (DPP-4) inhibitors are
a class of ADAs that increase the active level of
incretin, which enhances the secretion of insu-
lin, while suppressing pancreatic glucagon
secretion [10]. Because DPP-4 inhibitors have a
potent hypoglycemic efficacy as well as a low
risk of side effects, they are frequently pre-
scribed by clinicians worldwide.
As a result of their mechanism, DPP-4 inhi-
bitors are commonly believed to have a favor-
able effect on the secretory function of b-cells.
However, their effect on insulin sensitivity
remains controversial. In addition, studies
comparing the glycemic durability of DPP-4
inhibitors with other ADAs, especially with
TZDs, one of the most durable ADAs, are cur-
rently insufficient, although there were some
randomized controlled trials comparing gly-
cemic efficacy between TZDs and DPP-4 inhi-
bitors [11–13]. In terms of glycemic efficacy,
previous studies including the randomized
controlled trials have shown that DPP-4 inhi-
bitors were similar to or better than TZDs.
However, a retrospective cohort study pub-
lished in 2016 analyzed the glycemic durability
among three ADA classes, namely sulfonylureas,
TZDs, and DPP-4 inhibitors, as second-line
treatment with metformin, and concluded that
TZDs were the most durable agents, while DPP-4
inhibitors resulted in relatively poor durability
[14].
Hence, in the current study, we sought to
find clues for the differences in glycemic dura-
bility between TZDs and DPP-4 inhibitors by
comparing the insulin resistance and b-cell
function of patients with T2DM with good
glycemic control status.
METHODS
Patients and Data Collection
We conducted a retrospective cross-sectional
observational study on patients who visited the
diabetes center at Severance Hospital in Seoul,
South Korea during a 4-week period, from July
28 to August 21, 2014. A total of 241 patients
with T2DM who were treated with either TZDs
or DPP-4 inhibitors in combination with met-
formin for at least 1 year, regardless of other
ADAs, were included. Insulin users and patients
who were taking both TZDs and DPP-4 inhibi-
tors were excluded.
The study protocol received ethical approval
from the institutional review board at the
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Yonsei University College of Medicine (4-2018-
0699), and adhered to the tenets of the 1964
Helsinki declaration and its later amendments
or comparable ethical standards. Written
informed consent was not required in this study
because the database was only retrospectively
accessed for analytic purposes and personal
information was not used.
Measurements of Clinical and Laboratory
Parameters
Demographic data such as age, sex, body mass
index (BMI; kg/m2), and duration of diabetes
were retrospectively collected using electronic
medical records. The duration of diabetes was
defined from the date the patients were first
diagnosed by blood tests or from the first visit to
our clinic. Laboratory data, including serum
glucose, c-peptide, insulin, and glycated hemo-
globin (HbA1c), were acquired on the day of the
visit. The serum glucose was measured by the
standard glucose oxidase method using a 747
automatic analyzer (Hitachi, Tokyo, Japan), and
the HbA1c was checked by high-performance
liquid chromatography (Variant II; Bio-Rad,
Hercules, CA, USA). The serum insulin and
c-peptide levels were measured in duplicate by
immunoradiometric assay (Beckman Coulter,
Fullerton, CA, USA).
Study Outcomes (Endpoints)
The primary outcomes of the present study were
the insulin resistance and b-cell function of
patients with T2DM treated with TZDs vs. DPP-
4 inhibitors, as determined by the homeostasis
model assessment (HOMA), calculated using the
following formulas [15]:
HOMA-IR = (fasting insulin [lU/ml] 9 fast-
ing blood glucose [mg/dl])/405
HOMA-b = (360 9 fasting insulin [lU/ml])/
(Fasting blood glucose [mg/dl] - 63)
Statistical Analysis
The b-cell function and insulin resistance of
patients with T2DM were compared according
to their ADAs (TZD or DPP-4 inhibitor).
Student’s t test and the v2 test were used to
compare continuous and categorical variables
between the two groups. To minimize the
influence of demographic characteristics and to
compare the variables in patients under similar
glycemic control, we used propensity score
matching based on the patients’ baseline char-
acteristics and HbA1c level.
To find the independent variables signifi-
cantly correlated with b-cell function or insulin
resistance, we also performed simple correlation
analysis and multiple regression analysis.
Continuous variables are expressed as
mean ± standard deviation (SD), and categori-
cal variables as numbers and percentages (%).
RESULTS
Study Population Characteristics
A total of 241 patients with T2DM who were
treated with either TZDs or DPP-4 inhibitors in
combination with metformin for at least 1 year
were included in the present study (Fig. 1).
Pioglitazone was the only TZD prescribed in this
study, and three kinds of DPP-4 inhibitors,
namely sitagliptin, vildagliptin, and linagliptin,
were used. There were 109 patients taking sul-
fonylureas as triple therapy, accounting for
about 45% of patients in each group [60 (46.2%)
in the TZD group vs. 49 (44.1%) in the DPP-4
inhibitor group, p = 0.755]. The two treatment
groups had different baseline characteristics,
including sex and duration of diabetes
(Table S1; see Supplementary Material associ-
ated with this article online). Specifically, the
TZD group had a higher percentage of male
patients and longer duration of diabetes com-
pared with the DPP-4 inhibitor group.
After 1:1 propensity score matching, 84 pairs
of patients remained in this study (Table 1).
There were no significant differences in demo-
graphic variables and HbA1c between the TZD
and DPP-4 inhibitor groups. The mean age of
the patients was 62.2 years in the TZD group
and 62.5 years in the DPP-4 inhibitor group. In
both groups, the patients tended to be over-
weight [mean BMI 25.6 ± 3.4 (TZD group) vs.
25.9 ± 3.3 (DPP-4 inhibitor group), p = 0.553]
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and to have a long duration of diabetes
(11.5 ± 5.9 vs. 11.2 ± 6.9 years, p = 0.772). The
mean HbA1c of both groups was 6.8%
(51 mmol/mol), which is close to the glycemic
goal (6.8 ± 0.8%, 51.0 ± 8.8 mmol/mol vs.
6.8 ± 0.7%, 51.2 ± 8.1 mmol/mol, p = 0.873).
Insulin Resistance and b-Cell Function
of the Two Groups in the Propensity Score-
Matched Sample
Under the same degree of glycemic control, the
c-peptide and insulin levels of the TZD group
were lower than those in the DPP-4 inhibitor
group. The fasting c-peptide, postprandial
c-peptide, fasting insulin, and postprandial
insulin levels were 2.1 ± 0.8, 6.1 ± 2.3,
7.1 ± 4.8, and 34.9 ± 25.6 lU/mL in the TZD
group and 2.7 ± 1.3, 7.2 ± 3.2, 10.4 ± 8.4, and
46.7 ± 34.4 lU/mL in the DPP-4 inhibitor
group, respectively. When we measured the
insulin resistance by calculating the HOMA-IR,
the TZD group showed significantly better
insulin sensitivity (2.3 ± 1.9 vs. 3.5 ± 3.2,
p = 0.003) (Table 1, Fig. 2). On the other hand,
the HOMA-b, an index for the secretory func-
tion of b-cells, was markedly higher in the DPP-
4 inhibitor group compared with in the TZD
group (45.7 ± 31.6 vs. 61.4 ± 49.5, p = 0.016)
(Table 1, Fig. 3).
Independent Variables Correlated with b-
Cell Function or Insulin Sensitivity
In the simple correlation analysis, TZD was
found to be negatively correlated with HOMA-
IR, while DPP-4 inhibitors positively correlated
with HOMA-b. In addition, BMI and HbA1c
positively correlated with HOMA-IR, whereas
the HbA1c level and duration of diabetes nega-
tively correlated with HOMA-b (Table 2).
In the multiple regression analysis, HOMA-
IR was found to be independently associated
with ADAs (b = 1.14, p = 0.003), with TZD use
being independently associated with better
insulin sensitivity. Conversely, higher BMI and
Fig. 1 Schematic diagram for the study design. T2DM type 2 diabetes mellitus, MET metformin, TZD thiazolidinedione,
DPP-4i dipeptidyl peptidase 4 inhibitors, BMI body mass index, HbA1c glycated hemoglobin
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Fig. 2 Differences of insulin resistance between two
groups after matching with propensity score. TZD
thiazolidinedione, DPP-4i dipeptidyl peptidase 4
inhibitors
Fig. 3 Differences of b-cell function between two groups
after matching with propensity score. TZD thiazolidine-
dione, DPP-4i dipeptidyl peptidase 4 inhibitors
Table 1 Demographic and metabolic variables of both groups after matching with propensity scores
TZD DPP-4i p value
n 84 84
Age (years) 62.2 ± 9.9 62.5 ± 10.6 0.863
Men (n, %) 47 (56.0) 49 (58.3) 0.755
BMI (kg/m2) 25.6 ± 3.4 25.9 ± 3.3 0.553
Duration of diabetes (years) 11.5 ± 5.9 11.2 ± 6.9 0.772
Fasting serum glucose (mg/dL) 126.4 ± 27.0 132.4 ± 28.9 0.165
Postprandial serum glucose (mg/dL) 186.0 ± 65.3 209.7 ± 66.4 0.024
Fasting insulin (lU/mL) 7.1 ± 4.8 10.4 ± 8.4 0.002
Postprandial insulin (lU/mL) 34.9 ± 25.6 46.7 ± 34.4 0.013
Fasting c-peptide (lU/mL) 2.1 ± 0.8 2.7 ± 1.3 \ 0.001
Postprandial c-peptide (lU/mL) 6.1 ± 2.3 7.2 ± 3.2 0.007
HbA1c (%) 6.8 ± 0.8 6.8 ± 0.7 0.873
HOMA-IR 2.3 ± 1.9 3.5 ± 3.2 0.003
HOMA-b 45.7 ± 31.6 61.4 ± 49.5 0.016
Concomitant ADAs (n, %)
Sulfonylurea 31 (36.9) 38 (45.2) 0.272
Data are expressed as mean ± SD
TZD thiazolidinedione, DPP-4i dipeptidyl peptidase 4 inhibitors, BMI body mass index, HbA1c glycated hemoglobin,
HOMA-IR homeostasis model assessment of insulin resistance, HOMA-b homeostasis model assessment of b-cells, ADAs
antidiabetic agents
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HbA1c were independently associated with
worse insulin resistance (b = 0.25 and 1.12,
respectively, p\0.001) (Table 3).
In addition, DPP-4 inhibitors and higher BMI
were shown to be independent factors associ-
ated with higher b-cell secretory function
(b = 13.70 and 4.29, p = 0.024 and \ 0.001,
respectively) (Table 3).
DISCUSSION
In the present propensity score-matched analy-
sis, we compared the insulin resistance and b-
cell function of TZD and DPP-4 inhibitor users.
The study sample comprised patients with
T2DM who were taking TZD or DPP-4 inhibitors
as combination therapy with metformin for at
least 1 year. Although the duration of T2DM
Table 2 Simple correlation analysis to ﬁnd factors correlated to HOMA-IR or HOMA-b
HOMA-IR HOMA-b
r p value r p value
Age (years) - 0.11 0.172 - 0.15 0.056
Gender 0.03 0.683 0.12 0.138
BMI (kg/m2) 0.33 \ 0.001 0.39 \ 0.001
Duration of diabetes (years) - 0.04 0.588 - 0.23 0.003
HbA1c (%) 0.32 \ 0.001 - 0.16 0.038
ADAs; TZD-based (0) or DPP-4i-based (1) 0.30 \ 0.001 0.18 0.019
SU co-medication 0.08 0.286 - 0.13 0.087
HOMA-IR homeostasis model assessment of insulin resistance, HOMA-b homeostasis model assessment of b-cells, r cor-
relation coefﬁcient, BMI body mass index, HbA1c glycated hemoglobin, ADAs antidiabetic agents, TZD thiazolidinedione,
DPP-4i dipeptidyl peptidase 4 inhibitors, SU sulfonylurea
Table 3 Multivariate regression analysis of factors associated with insulin resistance and b-cell function
HOMA-IR HOMA-b
b p value b p value
Age - 0.02 0.468 - 0.24 0.469
Gender: male (0) or female (1) 0.12 0.762 3.89 0.527
BMI (kg/m2) 0.25 \ 0.001 4.29 \ 0.001
Duration of diabetes (years) - 0.02 0.599 - 0.83 0.147
HbA1c 1.12 \ 0.001 - 7.36 0.085
ADAs: TZD-based (0) or DPP-4i-based (1) 1.14 0.003 13.70 0.024
SU co-medication: no (0) or yes (1) 0.17 0.712 1.61 0.823
HOMA-IR homeostasis model assessment of insulin resistance, HOMA-b homeostasis model assessment of b-cells, b
regression coefﬁcient, BMI body mass index, HbA1c glycated hemoglobin, ADAs antidiabetic agents, TZD thiazolidine-
dione, DPP-4i dipeptidyl peptidase 4 inhibitors, SU sulfonylurea
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ranged from 1 to 39 years, the overall duration
tended to be long (mean duration
11.3 ± 6.4 years), and most patients were under
adequate glycemic control (mean HbA1c
6.8 ± 0.8, 51 mmol/mol). To minimize the
effects of different demographic characteristics
and to compare the variables in patients under
similar glycemic control, propensity score
matching was performed.
Under similar glycemic control and demo-
graphic factors, DPP-4 inhibitor users showed
higher serum insulin, c-peptide levels, and
HOMA-b, while TZD users had lower HOMA-IR
and HOMA-b. These findings reflect a situation
in which there is no need to secrete plenty of
insulin, owing to the lower insulin resistance in
TZD users. Regression analysis confirmed that
TZDs and DPP-4 inhibitors were independent
variables associated with insulin resistance and
b-cell function.
As T2DM usually progresses and finally leads
to b-cell failure, studies on the glycemic dura-
bility of ADAs have attracted the interest of
clinicians and researchers for a long time.
Comparing the glycemic durability of ADAs,
however, is not easy, because it requires a suf-
ficient number of controlled samples and long-
term follow-up data. Hence, there are currently
not enough well-organized, large-scale, popu-
lation-based studies on the durability of various
ADAs.
TZDs, which are insulin sensitizers, have
been consistently demonstrated to have excel-
lent glycemic durability in numerous studies.
ADOPT reported that rosiglitazone showed
superior glycemic durability as monotherapy for
T2DM compared with metformin and glyburide
[3]. As combination therapy with metformin,
pioglitazone also showed excellent glycemic
durability when compared with sulfonylurea
alone [4, 16], or with a sulfonylurea and DPP-4
inhibitor [14]. These results suggest that
improvement of insulin resistance might be
more beneficial for maintaining glycemic dura-
bility in terms of alleviating b-cell workloads.
The effect of DPP-4 inhibitors on insulin
resistance has been studied in several research
studies, but it was still controversial. Several
studies have shown that addition of DPP-4
inhibitor to the previous regimen or metformin
lowered insulin resistance [17, 18]. In contrast,
in some other studies, the addition of DPP-4
inhibitors significantly lowered blood glucose,
but insulin resistance was not improved com-
pared with placebo or other ADA [19, 20]. In the
present study, it was still not clear whether DPP-
4 inhibitors ameliorate insulin sensitivity, but
their influence on insulin resistance was not as
effective as TZDs.
Although the effect of DPP-4 inhibitors on
insulin sensitivity is not fully elucidated, they
are expected to provide relatively long-term
sustainable glycemic control, since their mech-
anism is considered to be more favorable than
that of sulfonylureas. In fact, some studies have
demonstrated results in line with this expecta-
tion. In a multinational, randomized, non-in-
feriority study reported in 2010, the addition of
sitagliptin to metformin resulted in similar
reduction of HbA1c after 2 years of treatment,
but favorable outcomes in terms of glycemic
durability, such as the slope of change in HbA1c
over time and b-cell function after a washout
period, compared with the addition of glipizide
[21]. Italian researchers reported that sitagliptin
as combination therapy provided a better
HbA1c-lowering efficacy after 5 years of treat-
ment, compared with sulfonylureas, pioglita-
zone, and metformin [22]. However, as
mentioned above, a retrospective cohort study
published in 2016 revealed worse glycemic
durability of DPP-4 inhibitors compared with
sulfonylureas and TZDs [14].
Some researchers have reported that incre-
tin-based ADAs such as DPP-4 inhibitors and
glucagon-like peptide 1 agonists stimulate b-cell
survival and preserve their mass and function in
animal models [23–25] and human studies [26],
supporting the long-term effectiveness of DPP-4
inhibitors for glycemic control, apart from
improvement of insulin sensitivity. For now,
though, there is little evidence in humans to
support durable disease-modifying effects of
DPP-4 inhibitors on b-cell mass or function
[27, 28]. Unsustainable effects of DPP-4 inhibi-
tors on b-cell function after drug washout have
been reported in previous research [29–31], and
these are in line with this notion.
Therefore, on the basis of the current state of
knowledge, improvement in insulin resistance
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is one of the most important and reasonable
methods for glycemic durability, because no
current ADA was proven to restore the mass or
survival of b-cells themselves, in the long term.
In the present study, TZD use was associated
with significantly improved insulin resistance
compared with DPP-4 inhibitor use in patients
with T2DM under similar glycemic control.
These results suggest that TZDs might be in a
more advantageous position for glycemic dura-
bility than DPP-4 inhibitors, in terms of insulin
resistance, in line with a previous retrospective
cohort study [14]. However, we should not
underestimate the effects of DPP-4 inhibitors,
improvement of the b-cell function, as unsus-
tainable effects. Long-term effects of DPP-4
inhibitors on b-cells are not sufficiently evalu-
ated, and well-designed, longitudinal studies
are needed. In addition, the effect of DPP-4
inhibitors on b-cells and TZDs’ insulin sensitiz-
ing effect might be mutually complementary,
suggesting that combination therapy would be
significantly effective. There were several stud-
ies in line with this notion [32–34].
Our study has some limitations. The size of
sample was relatively small, and the design was
a cross-sectional study. Therefore, we could not
describe conclusively the glycemic durability of
two ADAs, and this study showed us simply a
clue about it. For more critical evidence about
glycemic durability, well-designed, longitudi-
nal, prospective studies are needed. Information
about the lifestyle of the patients, including diet
and exercise, and other medications for co-
morbidities were not surveyed, so we could not
match for these factors before comparison.
However, we minimized the interference of
other demographic characteristics by using
propensity score matching. This study can be
considered meaningful because, to our knowl-
edge, it is the first study to compare the insulin
resistance and b-cell function of TZD- and DPP-
4 inhibitor-treated patients with T2DM with
similar glycemic control.
CONCLUSIONS
Under similar glycemic status, TZD users
showed more improved insulin resistance,
whereas DPP-4 inhibitor users secreted more
insulin from their b-cells. Well-designed, large-
scale, prospective studies are needed to clarify
the effect of DPP-4 inhibitors on insulin resis-
tance and b-cell function.
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